• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Vascular effects of aromatase inhibitors: data from clinical trials.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Howell, Anthony
    Cuzick, Jack
    Affiliation
    CRUK Department of Medical Oncology, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK. anthony.howell@christie-tr.nwest.nhs.uk
    Issue Date
    2005-05
    
    Metadata
    Show full item record
    Abstract
    Aromatase inhibitors (AIs) are becoming the endocrine treatment of first choice for postmenopausal women with hormone receptor-positive breast cancer and are under investigation for use in breast cancer prevention. AIs reduce circulating estrogen to barely detectable concentrations. It is possible that such a low concentration will be deleterious to the vascular system since estrogen receptors are known to be in the cell walls of blood vessels and estrogen is thought to be important in maintaining blood vessel integrity. Because most women who present with primary breast cancer are cured by surgery and systemic therapy and the major cause of female death is vascular disease, it is particularly important to investigate the vascular side effects of AIs in current breast cancer adjuvant and prevention trials. In order to set the vascular toxicities of AIs reported in the current adjuvant trials into context, here we compare them with the toxicities seen during treatment with hormone replacement therapy (HRT) and selective estrogen receptor modulators (SERMs). Clinical trial evidence indicates that HRT increases risk of coronary heart disease (CHD) whereas SERMs and AIs (to date) appear to be neutral. Cerebrovascular disease and venous thromboembotic events are increased by HRT and SERMs but appear to be unaffected by treatment with AIs. Cognitive function is also considered here since it may also have a vascular component and is potentially a serious potential side effect/benefit of AIs. Recent studies indicate that HRT has a small detrimental effect on cognitive function and is associated with a doubling of the incidence of dementia. A comprehensive study of the SERM, raloxifene, on cognitive function showed no significant effect. There are no definitive reported studies investigating tamoxifen and none for AIs on cognitive function, although there is one in progress in the context of the IBIS II prevention trial which compares anastrozole to placebo in women at high risk. At present concerns about deleterious vascular side effects are confined to HRT and SERMs. However, we have few long-term data using AIs for the treatment and prevention of breast cancer.
    Citation
    Vascular effects of aromatase inhibitors: data from clinical trials. 2005, 95 (1-5):143-9 J. Steroid Biochem. Mol. Biol.
    Journal
    The Journal of Steroid Biochemistry and Molecular Biology
    URI
    http://hdl.handle.net/10541/76575
    DOI
    10.1016/j.jsbmb.2005.04.005
    PubMed ID
    15936188
    Type
    Article
    Language
    en
    ISSN
    0960-0760
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.jsbmb.2005.04.005
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Is basic research providing answers if adjuvant anti-estrogen treatment of breast cancer can induce cognitive impairment?
    • Authors: Buwalda B, Schagen SB
    • Issue date: 2013 Oct 17
    • Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.
    • Authors: Mortimer JE, Urban JH
    • Issue date: 2003 May
    • Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    • Authors: Mouridsen HT
    • Issue date: 2006 Aug
    • Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    • Authors: Baumann CK, Castiglione-Gertsch M
    • Issue date: 2009 Dec
    • Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    • Authors: Gradishar WJ
    • Issue date: 2005
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.